Oramed Gets Positive Mid-stage Results From NASH Trial With ORMD-0801

September 13, 2022 — 09:46 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Oramed Pharmaceuticals Inc. (ORMP), a firm focused on oral drug delivery platforms, on Tuesday announced positive results from the Phase 2 trial which examined the safety and efficacy of its oral insulin candidate, ORMD-0801, with 8 mg twice daily dosing.

The trial was aimed to reduce liver fat content in Type 2 Diabetes patients with non-alcoholic steatohepatitis or NASH.

The trial also evaluated the effectiveness of ORMD-0801 in reducing liver fat content over the 12-week treatment period by observing several independent measures.

ORA-D-N02 is a Phase 2 double-blind, randomized, placebo-controlled, multicenter trial to assess the safety and efficacy of Oramed's oral insulin candidate, ORMD-0801, to reduce liver fat content in T2D patients with NASH.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Oramed Gets Positive Mid-stage Results From NASH Trial With ORMD-0801

Tags

Latest Articles